BactiQuant (BACTIQ) Q1 2025 TU earnings summary

Executive summary

• Achieved 34% sales growth in Q1 2025, driven by hardware deliveries and a solid sales pipeline.

• Delivered 8 online robot samplers, with 4 to a utility and 4 to the pharma segment.

• Pharma pilot project now generating recurring testkit consumption, supporting expected full-year growth.

Financial highlights

• Total Q1 2025 revenue reached DKK 2.56 million, up from DKK 1.92 million in Q1 2024.

• Hardware sales rose 149% year-over-year to DKK 1.22 million, while recurring revenue declined 9% to DKK 1.07 million.

• Other revenue increased 9% to DKK 0.27 million.

Outlook and guidance

• 2025 revenue expected between DKK 10–14 million; EBITDA guidance set at –8 to –11 million DKK.

• Liquidity is expected to be sufficient through the first half of 2026 based on current guidance.